Send to

Choose Destination
Radiother Oncol. 2010 Nov;97(2):212-6. doi: 10.1016/j.radonc.2010.09.021. Epub 2010 Oct 21.

(18)F-FDG PET bio-metabolic monitoring of neoadjuvant therapy effects in rectal cancer: focus on nodal disease characteristics.

Author information

Department of Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.



To evaluate efficacy of (18)F-FDG PET(CT) in the staging and re staging of patients with locally advanced rectal cancer, its potential role in predicting pathological response to neoadjuvant therapy.


Patients with confirmed diagnosis of rectal cancer (T2-4 or N+) were prospectively studied with (18)F-FDG PET before and after neoadjuvant therapy. Surgery was programmed 4-6 weeks after treatment followed by an expert histological analysis of the surgical specimen. Response to neoadjuvant treatment was assessed using two specific variables: difference in SUV (difSUV) pre/post-neoadjuvant treatment and response index (RI).


A total of 64 patients were enrolled for pathological and bio-metabolic response assessment. Compared to cN0, cN+ patients had a higher SUV(1) mean value (6.5 vs. 7.6, p=0.04) and ypN+ patients had higher SUV(2) mean values (2.4 vs 3.5, p=0.06). difSUV values of ≥4 was the most efficient diagnostic parameter (sensitivity=45.8%, specificity=86.2%, positive predictive value (PPV)=73.3%, negative predictive value(NPV)=65.7%). With an RI of 66.6%, the sensitivity was 38.5%, specificity=81.5%, PPV=66.6%, and NPV=57.8%. Patients who experienced disease progression had an RI≤66% and a difSUV≤4.


(18)F-FDG PET has proven to be an accurate diagnostic technique for assessing rectal cancer response to neoadjuvant therapy. The results in terms of sensitivity, specificity, PPV and NPV were similar, if not superior, to those reported with other diagnostic imaging techniques.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center